

press release

Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

- Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial¹
- Starting dose of Wegovy® pill (1.5 mg) available today for only \$149 per month (or \$5 per day) via easy to access self-pay offer
- Wegovy® pill now broadly available through 70,000+ US pharmacies such as CVS and Costco, select telehealth providers including Ro, LifeMD and Weight Watchers, NovoCare® Pharmacy, GoodRx and more

Plainsboro, NJ, US and Bagsværd, Denmark, January 5, 2026 – Wegovy® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity.² Wegovy® pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.³

“We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy® in a once-daily pill that demonstrated about 17% weight loss, if all patients stayed on treatment,” said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. “Wegovy® pill is here, and it represents a significant innovation as the first and only GLP-1 pill for weight loss. This moment is about changing what's possible in weight management, and to make that possible, we have worked to ensure Wegovy® pill is affordable and accessible to those who need it, however they choose to receive their care.”

Wegovy® is backed by proven results, as millions have been prescribed Wegovy® (semaglutide) injection 2.4 mg for weight management since 2021.⁴ Wegovy® pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials,

boasting an average weight loss of about 17% (16.6%), when used along with a reduced calorie diet and exercise and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo.^{*1} When looking at the efficacy regardless of if all patients stayed on treatment, an average weight loss of about 14% (13.6%) was achieved by people taking Wegovy® pill compared to about 2% (2.4%) for placebo.^{**1}

With once-daily oral dosing, Wegovy® pill can provide patients with a practical option as part of their daily routine to help people achieve meaningful weight loss.

OASIS 4 Results			
		Wegovy® pill 25 mg	Placebo
Percent weight reduction at 64 weeks ¹	If all patients stayed on treatment (Trial product estimand*)	~17%	~3%
	Analysis of all patients regardless of if they stayed on treatment (Treatment policy estimand**)	~14%	~2%

For Wegovy® pill based on baseline body weight of 235 lb., and for placebo based on baseline body weight of 231 lb.¹

In OASIS 4, common adverse reactions were similar to those previously seen in clinical trials with Wegovy® (semaglutide) injection 2.4 mg, including nausea, diarrhea, and vomiting.¹



Image of 1.5 mg starter dose of Wegovy® pill

Novo Nordisk continues to pursue innovative delivery models and strategic collaborations to meet people where they are, reaching more patients in more ways. This is designed to help patients obtain authentic, FDA-approved medicines and avoid potentially unsafe, unapproved alternatives. Wegovy® is available through a range of options including US pharmacies such as CVS and Costco, select telehealth providers including Ro, LifeMD and Weight Watchers, NovoCare® Pharmacy, GoodRx and others.

Wegovy® pill is available to all eligible patients with multiple affordability options. Self-pay patients can start at around \$5/day (\$149/month) for the starting dose of 1.5 mg. The 4 mg dose will also be available for \$149/month through April 15, 2026, then \$199/month after, and the highest doses of Wegovy® pill will be available for \$299. Commercially insured patients pay as little as \$25/month with the Wegovy® savings offer.[†]

Wegovy® pill is only approved in the US and will be available in 1.5 mg (starter dose), 4 mg, 9 mg, and 25 mg.³ For updates and information about the Wegovy® pill, please visit www.Wegovy.com.

* Based on the trial product estimand: estimated efficacy in an idealized scenario in which all patients stayed on treatment and took no other weight loss therapies.

** Based on the treatment policy estimand: treatment effect regardless of if patients stayed on treatment or took other weight loss therapies.

[†] Pay as little as \$25, subject to a maximum savings of \$100/month. Government beneficiaries excluded. Novo Nordisk reserves the right to modify or cancel this program at any time. See WegovyTerms.com for full terms.

About Wegovy® pill

Wegovy® pill is the first oral GLP-1 medicine for obesity in the US, and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off. Wegovy® pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease.³

The FDA approval of Wegovy® pill is based on the results from the OASIS 4 phase 3 clinical trial, which was a 64-week medical study that included 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes. Results showed that people taking Wegovy® pill once-daily along with a reduced calorie diet and exercise achieved an average weight loss of about 14% (13.6%) versus 2.4% with placebo.^{**} If all patients stayed on treatment, an average weight loss of about 17% (16.6%) was achieved by people taking Wegovy® pill compared to 2.7% for placebo.^{*} For those taking Wegovy® pill, 76% achieved 5% or greater body weight loss (from a baseline body weight of 235 lb) versus 31% taking placebo (from a baseline body weight of 231 lb).¹

About obesity

Obesity is a serious, chronic, progressive, and complex disease that requires long-term management.⁵⁻⁷ One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.^{5,7} Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.^{1,8}

What is Wegovy®?

Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg and Wegovy® (semaglutide) tablets 25 mg are prescription medicines used with a reduced-calorie diet and increased physical activity to:

- reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
- help adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.

Wegovy® (semaglutide) injection 1.7 mg or 2.4 mg is used with a reduced-calorie diet and increased physical activity to help children 12 years and older with obesity to lose weight and keep the weight off.

Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy® injection is safe and effective:

- to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 years
- to help children under 12 years of age lose weight and keep the weight off

It is not known if Wegovy® tablets are safe and effective for use in people under 18 years of age.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 78,500 people and markets products in roughly 170 countries. In the United States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs over 10,000 people across

more than 10 manufacturing, R&D and corporate locations in eight states plus Washington, D.C. For more information, visit novonordisk.com and novonordisk-us.com, and follow us on [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Liz Skrbkova (US)

+1 609 917 0632

USMediaRelations@novonordisk.com

Ambre James-Brown (Global)

+45 3079 9289

Globalmedia@novonordisk.com

Investors:

Frederik Taylor Pitter (US)

+1 609 613 0568

fpitr@novonordisk.com

Jacob Martin Wiborg Rode (Global)

+45 3075 5956

jrde@novonordisk.com

Sina Meyer (Global)

+45 3079 6656

azey@novonordisk.com

Christoffer Sho Togo Tullin (Global)

+45 3079 1471

cftu@novonordisk.com

Max Ung (Global)

+45 3077 6414

mxun@novonordisk.com

Alex Bruce (Global)

+45 34 44 26 13

axeu@novonordisk.com

References:

1. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. *N Engl J Med*. 2025; 393:1077-1087. DOI: 10.1056/NEJMoa2500969.
2. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: December 2025. Available at: <https://www.cdc.gov/obesity/adult-obesity-facts/index.html>.
3. Wegovy® (semaglutide) Prescribing Information. Plainsboro, NJ. Novo Nordisk Inc.
4. IQVIA LAAD Rx for the period of June 2021 to July 2024.
5. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. *Obesity*. 2018;26(1):61-69.
6. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obes Rev*. 2017;18(7):715-723.
7. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. *Endocr Pract*. 2016;22 (Suppl 3):1-203.
8. Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: December 2025. Available at: <https://www.cdc.gov/obesity/risk-factors/risk-factors.html>.